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Summary
An elevated body mass index (BMI) may make venipuncture more difficult, potentially impacting 
the use of home infusion (HI) and self-infusion (SI). We sought to determine whether above-
normal BMI is associated with decreased use of HI treatment and SI of clotting factor concentrate 
among haemophilic persons. We analysed data from 10 814 male patients with haemophilia A and 
B (45% with severe disease) aged 6–79 years enrolled in the Centers for Disease Control and 
Prevention Universal Data Collection surveillance project between 1998 and 2008. Associations 
between the use of HI and SI and BMI were evaluated using logistic regression. Fifty per cent of 
haemophilic men were overweight or obese, similar to rates reported among the general US 
population by the 2007–2008 National Health and Nutrition Examination Survey [Flegal, KM et 
al., JAMA 2010;303:235–241;]. Twenty per cent of children and 22% of teens were obese, as 
were 28% of adults [Ogden, CL et al., JAMA 2010;303:235, 242]. Overall, 70% of the study 
sample used HI; 44% of those who used HI also used SI. Overweight and obese men were each 
less likely to use HI than those of normal weight [odds ratio (OR) 0.8; 95% confidence interval 
(CI) 0.7–1.0 and OR 0.7; 95% CI 0.6–0.8 respectively]. Obese teens and adult men were also less 
likely to practice SI than teens and adults of normal weight (OR 0.8; 95% CI 0.7–0.9 for each). 
We conclude that overweight and obese haemophilic men are less likely to use HI and obese men 
are less likely to use SI than their normal-weight counterparts.
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Introduction
Haemophilia is an X-linked genetic disorder in which a deficiency of the coagulation 
proteins, factor VIII or factor IX leads to episodes of bleeding. Recurrent bleeding into joint 
space may lead to damage of the synovium, cartilage and bone, causing pain and disability. 
Treatment of bleeding events requires timely administration of clotting factor concentrate to 
treat or prevent life-or-limb-threatening injury, preferably within 2 h [1]. Factor replacement 
given regularly to prevent bleeding (prophylaxis) reduces the incidence of joint disease in 
haemophilic boys [2]. Infusing factor at home allows haemophilic persons to treat bleeds 
promptly and conveniently, enhancing adherence to more intensive treatment regimens such 
as prophylaxis. Home therapy use is associated with decreased risk for bleeding 
complications, improved quality of life, fewer school and work absences, and lower 
unemployment and hospitalization rates [3–5]. Home infusion (HI) treatment requires that 
the patient or a family member become proficient in the intravenous administration of 
clotting factor. Venipuncture can be challenging in obese patients because veins are more 
difficult to visualize [6,7]. Self-infusion (SI) is usually learned in adolescence. SI promotes 
treatment of bleeds with minimal delay, improves adherence to prophylaxis and increases 
patients’ independence [8].
Overweight and obesity in the US are public health concerns and continue to be a focus of 
public health efforts [9]. Thirty-three per cent of adult men in the general US population are 
obese, and 20% of boys and young men aged 6–19 [10]. A recent study found the 
prevalence of overweight and obesity among haemophilic men was similar to unaffected 
men, and the rate of loss in joint range of motion (ROM) was greater among overweight or 
obese men than among normal weight men [11]. European studies of haemophilic adults 
describe similar correlations between body mass index (BMI) and joint impairment [12,13].
Elevated body weight may decrease patients’ ability to home infuse and self- infuse. No 
previous studies have investigated the impact of body weight on specific haemophilia 
treatment practices. This study examines whether overweight and obesity are associated 
with decreased HI or SI.
Materials and methods
The Universal Data Collection (UDC) surveillance project was conducted by the Centers for 
Disease Control and Prevention (CDC) and 135 federally funded Hemophilia Treatment 
Centers (HTCs) in the United States to collect a uniform clinical outcomes data set on 
persons receiving comprehensive care in these centres. More than 18 000 male patients 
(85% of haemophilic persons receiving care at HTCs) were enrolled between 1998 and 2011 
[14,15]. From a study population of 13 037 men aged 6–79 years with haemophilia A or B, 
we excluded individuals with clinical or treatment characteristics having the potential to 
affect weight status. Exclusion criteria included a diagnosis of HIV (n = 1800) or 
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symptomatic liver disease (n = 236), inhibitor titre ≥5 Bethesda units (n = 245) and immune 
tolerance therapy at the time of the visit (n = 72). Individuals with incomplete height and 
weight data at their most recent UDC visit were also excluded (n = 133), yielding a final 
eligible study population of 10 814 persons enrolled from 1998 to 2008.
Demographic and clinical data were collected from UDC participants by HTC staff during 
annual clinic visits using a standardized data collection instrument. The registration form 
recorded age, gender, race, factor deficiency, diagnosis and baseline factor activity; the 
annual visit form collected date of visit, height, weight, insurance coverage, HI status, 
person performing infusion (self, family member or medical provider), central venous access 
device (CVAD) use and treatment regimen (episodic or prophylaxis). Data were recorded at 
each individual’s most recent UDC visit during 1998–2008.
Definition of variables
Centers for Disease Control and Prevention guidelines were used to define categories of 
overweight and obesity based on measured height and weight (Fig. 1). Participants with 
factor activity between 6% and 49% of normal levels were considered to have mild, 1–5% 
moderate, and <1%, severe haemophilia [3]. Participants were grouped into three age 
categories: children 6–11 years; teens 12–19 years; and adults 20 years and older. Treatment 
type was classified as episodic if the patient received products only to treat bleeding 
complications since the last annual clinic visit. Individuals were considered to use 
prophylaxis if they received treatment products to prevent bleeding or re-bleeding either 
continuously or on an intermittent schedule. Persons with commercial or public health care 
coverage were considered to be insured. Participants who received treatment products 
intravenously outside the medical setting (such as an HTC or emergency department) were 
considered to use HI. HI was performed either by the patient, a family member, or a medical 
care provider, such as a home health professional. Those who infused factor without help 
from others, such as parents or medical care providers, were considered to use SI.
Statistical methods
The prevalence of HI and SI (among those practising HI) was calculated for each level of 
demographic and clinical characteristics. Pearson’s chi-squared test or Fisher’s exact test 
were used to assess the statistical significance of associations in bivariate analyses. Logistic 
regression was used to assess the independent association of BMI with the use of HI and SI 
in multivariate analyses. Adjusted odds ratios (aOR) and 95% confidence intervals were 
computed. All statistical analyses were based on two-sided tests with a significance level of 
0.05, and conducted using SAS 9.3 (SAS Institute, Cary, NC, USA).
The analysis was conducted in four parts: (i) Frequency distributions of BMI categories and 
prevalence of HI and SI were calculated. (ii) Bivariate relationships of infusion use with 
elevated BMI and other demographic or clinical characteristics were calculated using chi-
squared tests. (iii) Multiple logistic regression models were developed to describe whether 
overweight and obesity were associated with the likelihood of HI and SI while adjusting for 
seven variables that were potential confounders: age, ethnicity, insurance status, 
haemophilia type and severity, treatment type and CVAD use. (iv) Controlling for the same 
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confounders, quartic polynomial logistic regression models using age as a continuous 
variable were created to illustrate the impact of BMI and advancing age on the prevalence of 
HI and SI. Figures based on these models illustrate the mean predicted probability of using 
HI and SI with advancing age among the largest subset of the sample population. This 
subset (n = 4721; 43% of sample population) included the most commonly occurring 
characteristics: white ethnicity, haemophilia A, no CVAD and having health care coverage).
Results
The sample included 10 814 male patients aged 6–79; 48% were adults aged 20–79. 
Seventy-six per cent had haemophilia A and 45% had severe haemophilia; 31% used 
prophylaxis. The mean age of the entire sample was 24; mean age of adults was 37. Sixty-
nine per cent of the sample was white; Hispanics were the largest minority group (13%). 
Ninety-four per cent had insurance.
Increased BMI
Overall, 36% of children, 38% of teens and 63% of adults had above-normal BMI. The 
prevalence of obesity as compared to overweight differed among adults and youth. A larger 
proportion of children and teens were obese (20% and 22% respectively) than were 
overweight (16% in both children and teens). Overweight (35%) affected a greater 
proportion of adults than did obesity (28%; P < 0.0001). Hispanic participants had the 
highest prevalence of elevated BMI among all ages. Multiple regression analysis among 
adults also revealed a significant association (P ≤ 0.0001) between increased BMI and mild 
haemophilic severity (Table 1).
Home infusion
Seventy per cent of male patients practised HI. Eight characteristics (Table 2) were 
associated (P < 0.0001) with increased HI use: age 12–19 (74%); African – American 
ethnicity (80%); severe haemophilia vs. moderate/mild disease (94% vs. 69% and 34%); 
haemophilia A vs. haemophilia B (72% vs. 65%); prophylaxis use (98% vs. 57%); CVAD 
use (95% vs. 68%) and normal or below-normal BMI (73%) vs. overweight (67%) and 
obesity (66%). These associations remained in the multivariable model. Although HI was 
associated with insurance coverage in the univariate analysis (P = 0.03, Table 2), this 
association diminished in the multivariate analysis (Table 4). Prophylaxis use is a 
confounder with severity, and we observed a trend effect between severity and HI use. 
Therefore, our analysis adjusted for both severity and treatment type; the effects of these 
interactions are illustrated in Figs 2 and 3.
Figures 2a and b compare the predicted probability of HI use by age and treatment regimen. 
Regardless of severity, HI use was more prevalent among persons using prophylaxis (Fig. 
2a) than among those treating episodically (Fig. 2b). For prophylaxis users, a difference in 
HI use among age and BMI categories was clearly observed only among those with mild 
disease. Use of HI was highest among 20–29-year-olds for all BMI groups. The rate of HI 
use climbed steadily during childhood through the mid-20s, but fell as BMI and age 
increased. Among adults, HI use was highest (75%) among those of normal weight and 
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lowest among the obese (63%). A trend of declining HI use with increasing BMI was also 
observed in teens (P = 0.057) and children (P = 0.040).
Self-infusion
Self-infusion was practised by 44% of those infusing at home. Tables 2 and 3 illustrate the 
univariate association between demographic and clinical characteristics and prevalence of 
SI. Table 2 displays the prevalence of SI and HI. Table 3 highlights the reduced use of SI 
with increased BMI among adults and teens. This association is not apparent in Table 2 
because of the inclusion of children aged 6–11, among whom there was no association 
between BMI and SI use. We observed a significantly higher SI prevalence (P < 0.0001, 
Table 2) among adults (71%); among those with severe haemophilia (vs. moderate/mild 
disease (47% vs. 41%, 40%); and among those using episodic vs. prophylactic treatment. 
The greater prevalence of SI use among persons on episodic treatment in Table 2 reflects the 
inclusion of children aged 6–11 (too young to self-infuse) using a prophylaxis. Table 3 
demonstrates the increased prevalence of SI among teens and adults using prophylaxis 
compared to episodic treatment (teens: 35% vs. 27%; P < 0.0001) adults: 79% vs. 69%, P < 
0.0001) There was no association between ethnicity (P = 0.13) or haemophilia type (P = 0.9) 
and SI use. Increased BMI was significantly associated with lower prevalence of SI among 
teens (P = 0.002) and adults (P = 0.005).
Self-infusion among teens—Self-infusion was practised by 32% of teens infusing at 
home. Use of SI in teens varied with severity (P < 0.0001): 36% of teens with severe disease 
used SI, compared to 27% of moderates and 20% of those with mild disease.
A significantly smaller proportion of teens with obesity used SI (P = 0.002) than did those 
with normal BMI (Table 3). Use of SI declined with increasing BMI. The disparity in SI 
prevalence among BMI categories peaked at age 16, when 39% of teens with normal or 
below-normal BMI used SI, compared to 27% of the overweight and 21% of the obese.
Self-infusion among adults—Self-infusion use among adults declined with decreasing 
haemophilic severity and was practised by 78% of those with severe disease, 66% of 
moderates, and 57% of those with mild disease (P < 0.0001, Table 3). A smaller proportion 
of obese persons used SI than those of normal weight. (P = 0.005, Table 3). The prevalence 
of SI among adults peaked at 76% between 30 and 39 years, declining to 36% by age 70–79.
Figures 3a and b compare the predicted probability of SI use by age and treatment regimen. 
The probability of SI use was highest among those with severe disease, regardless of 
treatment regimen, and lowest among those with mild disease treating episodically. SI use 
was lowest among the obese, regardless of age, severity or treatment regimen.
Table 4 illustrates the independent association (aOR) between BMI, HI and SI among the 
overall sample. The associations found in the bivariate analysis remained in the multiple 
logistic regression models. Obesity was negatively associated with HI use among adults and 
with SI in adults and teens after adjustment for other risk factors or confounders. Compared 
with persons of normal weight, overweight and obese persons were less likely to infuse at 
home (aOR = 0.84, 95% CI = 0.74–0.96 and aOR = 0.72; 95% CI = 0.63–0.82). Obese (but 
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not overweight) persons were less likely to self-infuse (aOR = 0.76, 95% CI = 0.66–0.88). 
Characteristics of persons with a higher probability of using HI included normal BMI, age > 
19, moderate/severe disease, non-Hispanic ethnicity and prophylaxis. Characteristics of 
persons with a higher probability of using SI included BMI of less than 30, age > 19, 
moderate/severe disease, and prophylaxis.
Discussion
BMI, home infusion and self-infusion
Home treatment affords immediate access to effective treatment. The ability to access home 
treatment has transformed the lives of haemophilic persons by reducing time to treatment 
and enabling adherence to prophylactic treatment. Prophylaxis involves frequent infusion of 
factor concentrate (1–4 times per week) and has been demonstrated to decrease episodes of 
joint bleeds and chronic arthropathy [2,16]. Home treatment has been shown to reduce pain 
and disability, hospitalizations, time lost from work or school, and to improve patients’ 
overall quality of life [17]. The probability graphs generated in this analysis (Fig. 2a and b) 
illustrate higher levels of HI use by those with moderate and severe disease and those using 
prophylaxis, after adjustment for other confounding variables.
Self-infusion allows patients to treat themselves conveniently at home, work, school, or 
while travelling. Bleeding episodes can be treated with minimal delay, a particularly 
important aspect of care for teenagers, who are often involved in sports and are physically 
very active. By facilitating timely treatment of a bleed, SI helps to preserve independence 
[18]. The increasing use of adult prophylactic regimens in developed countries adds to the 
need for SI skills [19]. We noted that SI use did not peak until 29–30 years among all 
severities, indicating that older teens and young adults may benefit from additional training.
This analysis suggests that obese persons with haemophilia are less likely to use HI and SI, 
possibly because of the increased difficulty of venipuncture caused by adiposity [6,7]. 
Additional studies designed to examine specific causes for the association between obesity 
and decreased use of HI and SI will advance our understanding of the interaction between 
these factors. The inability to perform HI and SI may lead to delayed treatment of bleeds, 
reduce the effectiveness of the treatment and place those with elevated BMI at increased risk 
of haemophilic complications.
Nearly 50% of haemophilic men were overweight or obese, similar to rates reported among 
the general US population by the 2007–2008 National Health and Nutrition Examination 
Survey [10,20].
Overweight and obese children are more likely to experience other poor health outcomes 
including high blood pressure, high cholesterol, impaired glucose tolerance, insulin 
resistance and type 2 diabetes, asthma, joint problems and fatty liver disease, and are at 
greater risk for social and psychological problems [21]. Moreover, youth with high BMI are 
more likely to become obese adults, a risk which increases with the degree of obesity 
[22,23].
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Obese adults face a greater risk of hypertension, type 2 diabetes, coronary heart disease, 
stroke, gallbladder disease, osteoarthritis, sleep apnoea, and colon cancer [20]. Persons with 
bleeding disorders and elevated BMI may face unique health complications in addition to 
those faced by the general population. Above-normal BMI has been associated with reduced 
ROM in haemophilic persons in American and European studies and can increase the cost of 
care, as dosing of factor concentrate is based on actual body weight [11–13,24].
The increasing prevalence of obesity among young men will continue to be an issue for both 
the general and haemophilia populations as this cohort ages into adulthood [10,20]. 
NHANES data collected between 2009 and 2010 indicate that the prevalence of obesity 
among the general US population has now reached a plateau among most age groups except 
male adolescents, among whom the prevalence continues to rise [25]. The teen years are 
critical for haemophilic persons because during this period treatment preferences and skills 
(including SI) are developed. Obesity may present increasing challenges for haemophilia 
providers as they teach adolescents to self-infuse at an appropriate age and in the most 
effective way possible.
In addition, among both the sample and general US populations we note 15% of youth aged 
6–19 have extreme obesity (BMI-for-age ≥97%), compared with only 4% of adults (BMI ≥ 
40). Given our finding that obesity is strongly associated with decreased use of HI and SI 
and the fact that young persons with extreme obesity are likely to remain obese as adults, 
these individuals may, on reaching adulthood, experience even lower rates of HI and SI use 
than adults observed in the sample. Youth with extreme obesity may comprise a future high-
risk group for whom interventions designed to increase the use of HI and SI may be 
beneficial.
Study limitations
Some limitations should be noted when interpreting the results of this analysis. Although we 
found statistically significant associations between elevated BMI, haemophilic severity and 
various treatments, we cannot determine from this cross-sectional data whether these 
associations are causal. Our sample population was derived solely from volunteer 
participants receiving care through federally funded HTCs, potentially limiting the 
application of our findings to all haemophilic persons, regardless of where they obtain care. 
The data reported in the UDC surveillance project were self-reported by the patient and 
treatment centre staff, but not confirmed with pharmacy or home care records. BMI as an 
indicator of obesity has limitations because it does not distinguish between fat mass and fat-
free mass; however, studies demonstrate that although the association between BMI and 
body fat can be weak among persons with lean body mass (such as athletes), it is strong 
among those with higher BMI levels [26]. Small sample size may be an issue in analyses of 
subgroups stratified simultaneously by numerous variables, such as persons with mild 
disease using prophylaxis.
Conclusion
This analysis suggests that obesity is associated with a lower prevalence of HI and SI of 
clotting factor concentrate among haemophilic men. Persons not using HI and SI risk 
ULLMAN et al. Page 7
Haemophilia. Author manuscript; available in PMC 2015 June 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
delayed treatment for bleeding episodes. The decline of HI and SI use with age indicates a 
need for further research into possible barriers to care and the development of interventions 
to encourage earlier and more prolonged use of these beneficial treatment options.
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Fig. 1. 
Centers for Disease Control and Prevention (CDC) body mass index (BMI) categories. 
Sources: Adults: Flegal, KM et al. JAMA (2010) 303:235–241; Children: Ogden, CL et al. 
JAMA (2010) 303:242.
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Fig. 2. 
(a) Predicted probability of home infusion (HI) use: prophylactic treatment (N = 1386). (b) 
Predicted probability of HI use: episodic treatment (N = 3335). Figure 2a and b illustrate a 
subset of the sample population with the following characteristics: (i) hemophilia A, (ii) 
Caucasian ethnicity, (iii) with health care coverage and (iv) without central venous access 
device.
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Fig. 3. 
(a) Predicted probability of self-infusion use: prophylactic treatment (N = 1365). (b) 
Predicted probability of self-infusion use: episodic treatment (N = 1864). Figure 3a and b 
illustrate a subset of the sample population with the following characteristics: (i) using home 
infusion, (ii) hemophilia A, (iii) Caucasian ethnicity, (iv) with health care coverage and (v) 
without central venous access device. The figures used in these graphs are not included in 
Tables 1–4.
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Table 2
Prevalence of home and self-infusion use by demographic and clinical characteristics.
Characteristic Home infusion no. (%) P value* Self-infusion no. (%)† P value
Male patients total (N = 10 814) 7571 (70) 3364 (44)
Age
 6–11 years 1530 (68) <0.0001 50 (3) <0.0001
 12–19 years 2498 (74) 789 (32)
 20 and older 3543 (69) 2525 (71)
Ethnicity
 White 5049 (68) <0.0001 2269 (45) 0.125
 Hispanic 990 (68) 405 (41)
 African American 973 (80) 438 (45)
 Other 559 (77) 252 (45)
Health insurance
 No 402 (66) 0.0323 210 (52) 0.001
 Yes 7169 (70) 3154 (44)
BMI status
 Normal weight or less 3994 (73) <0.0001 1622 (41) <0.0001
 Overweight 1849 (67) 982 (53)
 Obese 1728 (66) 760 (44)
Haemophilia type
 Haemophilia A 5886 (72) <0.0001 2617 (44) 0.933
 Haemophilia B 1685 (65) 747 (44)
Severity
 Mild 1096 (34) <0.0001 440 (40) <0.0001
 Moderate 1923 (69) 798 (41)
 Severe 4552 (94) 2126 (47)
Treatment type
 Episodic 4284 (57) <0.0001 2164 (51) <0.0001
 Prophylaxis 3287 (98) 1200 (37)
CVAD used
 No 6730 (68) <0.0001 3249 (48) <0.0001
 Yes 841 (95) 115 (14)
CVAD, central venous access device; BMI, body mass inidex.
*
P value calculated using chi-squared test.
†Among persons using home infusion.
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Table 3
Prevalence of home and self-infusion use by body mass index (BMI), severity and treatment type, age ≥12 
years.
Age group Characteristics Total† no. (%) Self-infusion no. (%) P value*
12–19 years N = 2498 N = 789
BMI category
 Normal weight or less 1576 (63) 535 (34) 0.002
 Overweight 406 (16) 120 (30)
 Obese 516 (21) 134 (26)
Severity
 Mild 294 (12) 58 (20) <0.0001
 Moderate 664 (27) 178 (27)
 Severe 1540 (62) 553 (36)
Treatment type
 Episodic 1123 (45) 306 (27) <0.0001
 Prophylaxis 1375 (55) 483 (35)
20 and older N = 3543 N = 2525
BMI category
 Normal weight or less 1436 (41) 1056 (74) 0.005
 Overweight 1194 (34) 854 (72)
 Obese 913 (26) 615 (67)
Severity
 Mild 668 (19) 381 (57) <0.0001
 Moderate 918 (26) 609 (66)
 Severe 1957 (55) 1535 (78)
Treatment type
 Episodic 2681 (76) 1844 (69) <0.0001
 Prophylaxis 862 (24) 681 (79)
*
P value calculated using chi-squared test.
†
The percentages used in the total sample column (those on home infusion) sum to 100% by characteristic; in the self-infusion column, the 
denominator for each percentage is the number of home infusers in that subgroup.
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Table 4
Independent association of BMI status with home infusion and self-infusion.
Characteristic
Home infusion
N = 10 814
Self-infusion
N = 7571
aOR (95% CI)* P value aOR (95% CI) P value
Age (vs. 20 and older)
 6–11 years 0.40 (0.34–0.46) <0.0001 0.01 (0.01–0.02) <0.0001
 12–19 years 0.85 (0.75–0.97) 0.013 0.15 (0.13–0.17) <0.0001
Ethnicity (vs. White)
 Hispanic 0.82 (0.70–0.96) 0.015 1.17 (0.98–1.39) 0.084
 African American 1.11 (0.93–1.34) 0.256 1.16 (0.97–1.37) 0.097
 Other 1.13 (0.90–1.41) 0.300 1.12 (0.90–1.39) 0.315
Health insurance (vs. no)
 Yes 1.18 (0.96–1.44) 0.110 1.17 (0.92–1.49) 0.190
BMI status (vs. normal weight or less)
 Overweight 0.84 (0.74–0.96) 0.009 0.92 (0.80–1.06) 0.234
 Obese 0.72 (0.63–0.82) <0.0001 0.76 (0.66–0.88) 0.0002
Haemophilia type (vs. haemophilia A)
 Haemophilia B 0.83 (0.74–0.94) 0.002 0.82 (0.71–0.93) 0.003
Severity (vs. mild)
 Moderate 3.83 (3.41–4.31) <0.0001 1.56 (1.30–1.86) <0.0001
 Severe 14.41 (12.38–16.77) <0.0001 2.45 (2.07–2.90) <0.0001
Treatment type (vs. episodic)
 Prophylaxis 12.81 (9.80–16.74) <0.0001 1.22 (1.06–1.39) 0.005
CVAD used (vs. no)
 Yes 2.53 (1.75–3.65) <0.0001 0.32 (0.26–0.41) <0.0001
CI, confidence interval; CVAD, central venous access device; BMI, body mass inidex.
*
aOR, adjusted odds ratio calculated using one multivariable logistic regression that adjusted for all covariates in the table.
Haemophilia. Author manuscript; available in PMC 2015 June 15.
